As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute and Dana-Farber/Boston Children's Cancer and Blood Disorders Center showcased their advances at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, in December of 2015.
As the premier conference in the field, the ASH Annual Meeting attracts more than 20,000 experts who share their advances in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, as well as other blood disorders.
Attendees visited our Dana-Farber and Dana-Farber/Boston Children’s booths to connect with our adult and pediatric physicians and scientists – and learn more about our discoveries, innovations, and clinical trials.
Join the Twitter conversation at #ASH15Follow us on LinkedIn
On December 7, conference attendees heard Paul Richardson, MD, clinical program leader and director of clinical research at Dana-Farber’s Jerome Lipper Multiple Myeloma Center and the R.J. Corman professor of Medicine at Harvard Medical School, as he presented ASH’s 2015 Ernest Beutler Lecture with Alfred Goldberg, PhD. The lecture topic was, "Understanding the Proteasome: from Protein Degradation to Disease Therapy."
At this year’s meeting, many renowned Dana-Farber and Dana-Farber/Boston Children’s experts in hematological malignancies and hematology shared their discoveries, innovations, and insights from their adult and pediatric research and clinical practice.
Download these rosters of select Dana-Farber and Dana-Farber/Boston Children’s conference speakers:
ASH 2015 Dana-Farber SpeakersASH 2015 Dana-Farber/Boston Children's Speakers
At Dana-Farber and Dana-Farber/Boston Children’s, we’re proud of our leadership role – at the Annual Meeting, and in the Society itself. Dana-Farber/Boston Children’s pediatric oncologist David Williams, MD, is 2015 ASH president. And Dana-Farber medical oncologist Kenneth Anderson, MD, is 2015 ASH vice president and 2016 ASH president-elect.
ASCO POST Newsreel: 'Dana-Farber's Richard M. Stone, MD, discusses the RATIFY trial, an international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly disagnosed acute myeloid leukemia with FLT3 mutations'
OncLive: 'Midostaurin Shows Rare Survival Improvement in FLT3-Mutated AML'
OncologyNurseAdvisor: 'Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL'
Medscape: 'Rituximab + Chemo: New Standard of Care for BCP-ALL?'
Cancer Therapy Advisor: 'Nidostaurin Prolongs Survival in Patients with Newly Diagnosed AML'
Medscape: 'Midostaurin in AML: First Targeted Agent Improves Survival'
Dana-Farber experts presented exciting new research findings at the 2015 conference. Presentations included:
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: